---
symbol: "HIMS"
name: "Hims & Hers"
date: 2026-08-05
change_pct: 3.353421461897357
direction: "up"
event_type: "theme_sympathy"
url: "https://perplo.app/why/HIMS/2026-08-05"
updated_at: 2026-08-05T11:06:50.690Z
---

# Why Hims & Hers (HIMS) rose 3.35% on August 5, 2026

Hims & Hers (HIMS) rose 3.35% on August 5, 2026 — Lilly's blockbuster lifts GLP-1 / obesity peers.

## What happened

Eli Lilly easily topped quarterly estimates and raised 2026 revenue guidance on surging Zepbound and Mounjaro sales, triggering a broad GLP-1 / Obesity theme rally that lifted Hims alongside its peers.

## Why it moved

Lilly's beat and raise validate GLP-1 demand tailwinds and supply normalization — the macro backdrop for all obesity-therapy players; Hims benefits from the rising tide of category enthusiasm and reduced narrative risk…

## Why it matters

Hims is a secondary beneficiary of the GLP-1 / Obesity supercycle recovery — Lilly's earnings win proves the narrative is intact and durability fears are overblown, restoring conviction in the entire theme and lifting…

## What would break the thesis

If Hims' own earnings or guidance disappoint in coming quarters, or if Lilly's supply-chain caution resurfaces, Hims will lose the sympathy support and re-test lows.

## Sources

- [Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge](https://www.cnbc.com/2026/08/05/eli-lilly-lly-earnings-q2-2026.html) — CNBC

---

Trade HIMS perpetual futures 24/7 onchain: https://perplo.app/asset/HIMS